Veeva Systems (VEEV) Stock Price, Fundamentals & Analysis

What VEEV does

Veeva Systems (VEEV) is a stock in the Healthcare sector, specifically in the Health Information Services industry, headquartered in Pleasanton, United States. The company provides cloud-based software for the life sciences industry across North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. Its offerings include the Veeva Commercial Cloud, which features Veeva Vault CRM Suite for pharmaceutical and biotechnology companies, Veeva Medical for multi-channel medical content, Veeva PromoMats for content and digital asset management, and Veeva Crossix for pharmaceutical brand analytics. Additionally, Veeva provides the Veeva Data Cloud, including Veeva OpenData for customer reference data, Veeva Link for deep data, Veeva Compass with de-identified and longitudinal patient data, and Veeva CRM Pulse for access and multichannel engagement metrics. As a major player in its field, VEEV is part of the S&P 500.

Key numbers explained

• The current price is 270.75 USD, reflecting the latest trading value of one share.
• The trailing P/E ratio of 44.3 is a valuation metric that compares the stock's price to its last 12 months of earnings; a higher number can indicate investors expect strong future growth.
• The forward P/E ratio of 26.4 uses expected future earnings, offering a look at how the market values the company's growth prospects.
• Earnings per share for the trailing 12 months is 6.11 USD, representing the portion of the company's profit allocated to each outstanding share.
• The dividend yield is 0%, meaning the company pays no cash dividend, so the share of earnings paid out as dividends is also 0%.
• The beta of 0.97 suggests the stock's price tends to move slightly less than the overall market.
• The priceToBook ratio of 6.04 compares the market value to the company's book value, indicating how much investors are willing to pay per dollar of net assets.

Recent news

Recent headlines indicate that Veeva has unveiled the Falcon Router to streamline biopharma case routing and that Vault CRM has extended its market leadership as another top 20 biopharma company chooses Veeva. Other news items focus on market analyses for the eClinical Solutions and Pharmacovigilance Software markets, alongside a retrospective on a $1000 investment in Veeva Systems from 10 years ago. The company has also expanded its partnership with Amgen through a global Vault CRM rollout plan.

What to watch

For investors tracking VEEV, general factors to watch include the company's revenue growth, which has been 17.6% year over year, and its profit margins, with a profitMargin of 29.3% and an operatingMargin of 29.6%. The returnOnEquity of 14.4% and the debt-to-equity ratio of 2 are also key indicators of financial health. The stock's performance over the last 52 weeks, ranging from 148.05 to 310.5, and its current price change over the last 52 weeks of -6.1% provide context for its volatility. As a peer in the healthcare space, investors might also compare VEEV to companies like Cencora (COR), Zoetis (ZTS), Elevance Health (ELV), Align Technology (ALGN), Boston Scientific (BSX), Quest Diagnostics (DGX), and McKesson Corporation (MCK). The next earnings date is Nov 25, 2026.